Evaluation of Concomitant Systemic Treatment in Older Adults With Head and Neck Squamous Cell Carcinoma Undergoing Definitive Radiotherapy
Authors: Alexander Rühle, Sebastian Marschner, Marlen Haderlein, Alexander Fabian, Maria Weymann, Max Behrens, Carolin Senger, Daniel R. Dickstein, Johannes Kraft, Jens von der Grün, Eric Chen, Todd Aquino-Michaels, Justus Domschikowski, Amanda Bickel, Alev Altay-Langguth, Goda Kalinauskaite, Victor Lewitzki, Konstantinos Ferentinos, Constantinos Zamboglou, Sören Schnellhardt, Erik Haehl, Simon K.B. Spohn, Eleni Gkika, Daniela Zöller, Matthias Guckenberger, Volker Budach, Claus Belka, Richard Bakst, Arnulf Mayer, Heinz Schmidberger, Anca-Ligia Grosu, Panagiotis Balermpas, Carmen Stromberger, Nils H. Nicolay
Journal: JAMA Network Open (2023)

Importance The number of older adults with head and neck squamous cell carcinoma (HNSCC) is increasing, and these patients are underrepresented in clinical trials. It is unclear whether the addition of chemotherapy or cetuximab to radiotherapy is associated with improved survival in older adults with HNSCC. Objective To examine whether the addition of chemotherapy or cetuximab to definitive radiotherapy is associated with improved survival in patients with locoregionally advanced (LA) HNSCC. Design, Setting, and Participants The Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy (SENIOR) study is an international, multicenter cohort study including older adults (≥65 years) with LA-HNSCCs of the oral cavity, oropharynx/hypopharynx, or larynx treated with definitive radiotherapy, either alone or with concomitant systemic treatment, between January 2005 and December 2019 at 12 academic centers in the US and Europe. Data analysis was conducted from June 4 to August 10, 2022. Interventions All patients underwent definitive radiotherapy alone or with concomitant systemic treatment. Main Outcomes and Measures The primary outcome was overall survival. Secondary outcomes included progression-free survival and locoregional failure rate. Results Among the 1044 patients (734 men [70.3%]; median [IQR] age, 73 [69-78] years) included in this study, 234 patients (22.4%) were treated with radiotherapy alone and 810 patients (77.6%) received concomitant systemic treatment with chemotherapy (677 [64.8%]) or cetuximab (133 [12.7%]). Using inverse probability weighting to attribute for selection bias, chemoradiation was associated with longer overall survival than radiotherapy alone (hazard ratio [HR], 0.61; 95% CI, 0.48-0.77; P &amp;amp;lt; .001), whereas cetuximab-based bioradiotherapy was not (HR, 0.94; 95% CI, 0.70-1.27; P = .70). Progression-free survival was also longer after the addition of chemotherapy (HR, 0.65; 95% CI, 0.52-0.81; P &amp;amp;lt; .001), while the locoregional failure rate was not significantly different (subhazard ratio, 0.62; 95% CI, 0.30-1.26; P = .19). The survival benefit of the chemoradiation group was present in patients up to age 80 years (65-69 years: HR, 0.52; 95% CI, 0.33-0.82; 70-79 years: HR, 0.60; 95% CI, 0.43-0.85), but was absent in patients aged 80 years or older (HR, 0.89; 95% CI, 0.56-1.41). Conclusions and Relevance In this cohort study of older adults with LA- HNSCC, chemoradiation, but not cetuximab-based bioradiotherapy, was associated with longer survival compared with radiotherapy alone.